116 related articles for article (PubMed ID: 37269933)
1. Pristimerin protects against pathological cardiac hypertrophy through improvement of PPARα pathway.
Lu Y; Zeng Z; Bao X; Wu M; Jing Z; Feng J
Toxicol Appl Pharmacol; 2023 Aug; 473():116572. PubMed ID: 37269933
[TBL] [Abstract][Full Text] [Related]
2. Puerarin ameliorated pressure overload-induced cardiac hypertrophy in ovariectomized rats through activation of the PPARα/PGC-1 pathway.
Hou N; Huang Y; Cai SA; Yuan WC; Li LR; Liu XW; Zhao GJ; Qiu XX; Li AQ; Cheng CF; Liu SM; Chen XH; Cai DF; Xie JX; Chen MS; Luo CF
Acta Pharmacol Sin; 2021 Jan; 42(1):55-67. PubMed ID: 32504066
[TBL] [Abstract][Full Text] [Related]
3. Gramine protects against pressure overload-induced pathological cardiac hypertrophy through Runx1-TGFBR1 signaling.
Xu L; Su Y; Yang X; Bai X; Wang Y; Zhuo C; Meng Z
Phytomedicine; 2023 Jun; 114():154779. PubMed ID: 37023527
[TBL] [Abstract][Full Text] [Related]
4. Lupeol protects against cardiac hypertrophy via TLR4-PI3K-Akt-NF-κB pathways.
Li D; Guo YY; Cen XF; Qiu HL; Chen S; Zeng XF; Zeng Q; Xu M; Tang QZ
Acta Pharmacol Sin; 2022 Aug; 43(8):1989-2002. PubMed ID: 34916609
[TBL] [Abstract][Full Text] [Related]
5. Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice.
Zhang ZZ; Shang QH; Jin HY; Song B; Oudit GY; Lu L; Zhou T; Xu YL; Gao PJ; Zhu DL; Penninger JM; Zhong JC
J Transl Med; 2013 Sep; 11():229. PubMed ID: 24067190
[TBL] [Abstract][Full Text] [Related]
6. Zonisamide attenuates pressure overload-induced myocardial hypertrophy in mice through proteasome inhibition.
Wu Q; Liu WJ; Ma XY; Chang JS; Zhao XY; Liu YH; Yu XY
Acta Pharmacol Sin; 2024 Apr; 45(4):738-750. PubMed ID: 38097716
[TBL] [Abstract][Full Text] [Related]
7. Activated FMS-like tyrosine kinase 3 ameliorates angiotensin II-induced cardiac remodelling.
Ma W; Liang F; Zhan H; Jiang X; Gao C; Zhang X; Zhang K; Sun Q; Hu H; Zhao Z
Acta Physiol (Oxf); 2020 Oct; 230(2):e13519. PubMed ID: 32480429
[TBL] [Abstract][Full Text] [Related]
8. Alarin moderated myocardial hypertrophy via inhibiting cyclic adenosine monophosphate/protein kinase A signaling pathway to attenuate autophagy.
Shen T; Liu Y; Dong S; Xu X; Wang X; Li Y; Zhou L
Peptides; 2021 Dec; 146():170669. PubMed ID: 34624429
[TBL] [Abstract][Full Text] [Related]
9. Melatonin protects against the pathological cardiac hypertrophy induced by transverse aortic constriction through activating PGC-1β: In vivo and in vitro studies.
Zhai M; Liu Z; Zhang B; Jing L; Li B; Li K; Chen X; Zhang M; Yu B; Ren K; Yang Y; Yi W; Yang J; Liu J; Yi D; Liang H; Jin Z; Reiter RJ; Duan W; Yu S
J Pineal Res; 2017 Oct; 63(3):. PubMed ID: 28708271
[TBL] [Abstract][Full Text] [Related]
10. Hyperoside Protects Against Pressure Overload-Induced Cardiac Remodeling via the AKT Signaling Pathway.
Wang X; Liu Y; Xiao L; Li L; Zhao X; Yang L; Chen N; Gao L; Zhang J
Cell Physiol Biochem; 2018; 51(2):827-841. PubMed ID: 30466089
[TBL] [Abstract][Full Text] [Related]
11. Delphinidin attenuates pathological cardiac hypertrophy via the AMPK/NOX/MAPK signaling pathway.
Chen Y; Ge Z; Huang S; Zhou L; Zhai C; Chen Y; Hu Q; Cao W; Weng Y; Li Y
Aging (Albany NY); 2020 Mar; 12(6):5362-5383. PubMed ID: 32209725
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor 21 protects the heart from angiotensin II-induced cardiac hypertrophy and dysfunction via SIRT1.
Li S; Zhu Z; Xue M; Yi X; Liang J; Niu C; Chen G; Shen Y; Zhang H; Zheng J; Zhao C; Liang Y; Cong W; Wang Y; Jin L
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1241-1252. PubMed ID: 30677512
[TBL] [Abstract][Full Text] [Related]
13. Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+/CaMKII pathway.
Wei X; Jin J; Wu J; He Y; Guo J; Yang Z; Chen L; Hu K; Li L; Jia M; Li Q; Lv X; Ge F; Ma S; Wu H; Zhi X; Wang X; Jiang L; Osto E; Zhang J; Meng D
Cardiovasc Res; 2023 Aug; 119(9):1842-1855. PubMed ID: 37279500
[TBL] [Abstract][Full Text] [Related]
14. ANGPTL8 is a negative regulator in pathological cardiac hypertrophy.
Hu L; Wei J; Zhang Y; Wang Z; Tang J; Tang J; Gao Y; Zhang X; Li Y; Liu Y; Ma S; Guo X; Zhang Q
Cell Death Dis; 2022 Jul; 13(7):621. PubMed ID: 35851270
[TBL] [Abstract][Full Text] [Related]
15. EndophilinA2 protects against angiotensin II-induced cardiac hypertrophy by inhibiting angiotensin II type 1 receptor trafficking in neonatal rat cardiomyocytes.
Liu Y; Shen HJ; Wang XQ; Liu HQ; Zheng LY; Luo JD
J Cell Biochem; 2018 Nov; 119(10):8290-8303. PubMed ID: 29923351
[TBL] [Abstract][Full Text] [Related]
16. Baicalin Attenuates Cardiac Dysfunction and Myocardial Remodeling in a Chronic Pressure-Overload Mice Model.
Zhang Y; Liao P; Zhu M; Li W; Hu D; Guan S; Chen L
Cell Physiol Biochem; 2017; 41(3):849-864. PubMed ID: 28214892
[TBL] [Abstract][Full Text] [Related]
17. The nuclear receptor RORα protects against angiotensin II-induced cardiac hypertrophy and heart failure.
Beak JY; Kang HS; Huang W; Myers PH; Bowles DE; Jetten AM; Jensen BC
Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H186-H200. PubMed ID: 30387679
[TBL] [Abstract][Full Text] [Related]
18. De-ubiquitination of p300 by USP12 Critically Enhances METTL3 Expression and Ang II-induced cardiac hypertrophy.
Lu P; Xu Y; Sheng ZY; Peng XG; Zhang JJ; Wu QH; Wu YQ; Cheng XS; Zhu K
Exp Cell Res; 2021 Sep; 406(1):112761. PubMed ID: 34339675
[TBL] [Abstract][Full Text] [Related]
19. SUMOylation of SIRT1 activating PGC-1α/PPARα pathway mediates the protective effect of LncRNA-MHRT in cardiac hypertrophy.
Liu MY; Yue LJ; Luo YC; Lu J; Wu GD; Sheng SQ; Shi YQ; Dong ZX
Eur J Pharmacol; 2022 Sep; 930():175155. PubMed ID: 35863508
[TBL] [Abstract][Full Text] [Related]
20. Polyphyllin I attenuates pressure over-load induced cardiac hypertrophy via inhibition of Wnt/β-catenin signaling pathway.
Li Q; Jiang W; Wan Z; Ni Y; Lei L; Wei J
Life Sci; 2020 Jul; 252():117624. PubMed ID: 32259602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
